JP2010536766A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536766A5
JP2010536766A5 JP2010521080A JP2010521080A JP2010536766A5 JP 2010536766 A5 JP2010536766 A5 JP 2010536766A5 JP 2010521080 A JP2010521080 A JP 2010521080A JP 2010521080 A JP2010521080 A JP 2010521080A JP 2010536766 A5 JP2010536766 A5 JP 2010536766A5
Authority
JP
Japan
Prior art keywords
hydrogen
phenyl
compound according
compound
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521080A
Other languages
English (en)
Japanese (ja)
Other versions
JP5385904B2 (ja
JP2010536766A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/072049 external-priority patent/WO2009023453A1/en
Publication of JP2010536766A publication Critical patent/JP2010536766A/ja
Publication of JP2010536766A5 publication Critical patent/JP2010536766A5/ja
Application granted granted Critical
Publication of JP5385904B2 publication Critical patent/JP5385904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521080A 2007-08-14 2008-08-04 γ−セクレターゼ阻害剤 Expired - Fee Related JP5385904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
US60/955,720 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (3)

Publication Number Publication Date
JP2010536766A JP2010536766A (ja) 2010-12-02
JP2010536766A5 true JP2010536766A5 (enExample) 2011-09-22
JP5385904B2 JP5385904B2 (ja) 2014-01-08

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521080A Expired - Fee Related JP5385904B2 (ja) 2007-08-14 2008-08-04 γ−セクレターゼ阻害剤

Country Status (11)

Country Link
US (1) US8188069B2 (enExample)
EP (1) EP2178844A1 (enExample)
JP (1) JP5385904B2 (enExample)
KR (1) KR101136260B1 (enExample)
CN (1) CN101778826B (enExample)
AU (1) AU2008287124B2 (enExample)
BR (1) BRPI0815135A2 (enExample)
CA (1) CA2694209C (enExample)
EA (1) EA017286B1 (enExample)
MX (1) MX2010001754A (enExample)
WO (1) WO2009023453A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯二氮呯酮化合物
WO2013036679A1 (en) * 2011-09-07 2013-03-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6486272B2 (ja) 2012-09-07 2019-03-20 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞および/または支持細胞再生のための方法および組成物
JP2015533811A (ja) 2012-09-21 2015-11-26 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company N−置換ビス(フルオロアルキル)1,4−ベンゾジアゼピノン化合物
CN104854094A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 氟烷基二苯并二氮杂*酮化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
EP2897947B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
WO2014047397A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
US9492469B2 (en) 2013-04-04 2016-11-15 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
MX380780B (es) 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス, インコーポレイテッド 蝸牛シナプス障害を処置する方法
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
KR20250151605A (ko) 2018-06-01 2025-10-21 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) * 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
US7468365B2 (en) * 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
WO2004080983A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel lactams and uses thereof

Similar Documents

Publication Publication Date Title
JP2010536766A5 (enExample)
JP2009535462A5 (enExample)
JP2010501534A5 (enExample)
JP2009149903A5 (enExample)
JP2010530897A5 (enExample)
JP2010519270A5 (enExample)
JP2007269812A5 (enExample)
JP2013505929A5 (enExample)
JP2010534247A5 (enExample)
JP2012121931A5 (enExample)
JP2011500769A5 (enExample)
JP2007522220A5 (enExample)
JP2013010749A5 (ja) カルバゾール化合物
JP2009545527A5 (enExample)
JP2011510079A5 (enExample)
JP2013507423A5 (enExample)
JP2011512324A5 (enExample)
JP2007519721A5 (enExample)
JP2010520214A5 (enExample)
JP2014028916A5 (enExample)
JP2010508310A5 (enExample)
JP2010534246A5 (enExample)
JP2010500432A5 (enExample)
JP2011037885A5 (enExample)
JP2011016798A5 (enExample)